Table 2.

Variables correlating with inferior PFS in the CCD cohort (n = 87)


Variable		n (%)Univariate analysisMultivariate analysis
HR95% CIPHR95% CIP
Age > 60 y 50 (57) 1.2 0.7-1.9 .56    
Stage III/IV 72 (83) 3.0 1.3-6.9 .01 5.1 1.1-22.5 .03 
Performance: ECOG PS ≥ 2 10 (11) 1.9 0.9-3.7 .08    
LDH elevated 53 (61) 1.1 0.7-1.9 .69    
BM involvement (by morphological assessment) 32 (37) 2.3 1.4-3.9 .002 3.0 1.1-8.4 .04 
Other extranodal sites of involvement 35 (40) 1.9 1.1-3.1 .01 1.5 0.7-3.3 .32 
IPI score        
0-1 17 (20) 1.0      
2 28 (32) 2.1 0.9-4.7 .08 1.0 0.2-4.3 .98 
3 30 (34) 2.9 1.3-6.5 .009 0.4 0.1-2.8 .35 
4-5 12 (14) 2.8 1.1-7.0 .03 0.1 0.01-2.0 .15 
PIT score        
0-1 44 (51) 1.0      
2 24 (28) 1.3 0.7-2.4 .37 1.3 0.4-3.8 .65 
3-4 19 (22) 2.2 1.2-4.1 .01 2.4 0.3-17.0 .41 
Histology        
PTCL-NOS 28 (32) 1.0      
PTCL-TFH 6 (7) 0.3 0.1-1.1 .08    
AITL 39 (45) 0.7 0.4-1.2 .14    
ALK+ ALCL 2 (2) 0.3 0.04-2.3 .24    
ALK− ALCL 8 (9) 0.4 0.1-1.2 .10    
MEITL 4 (5) 0.7 0.2-2.5 .61    
Use of etoposide-containing regimens 47 (54) 1.0 0.6-1.6 .91    
Use of BV-containing regimens 12 (14) 0.8 0.3-2.0 .65    
ASCT consolidation 37 (43) 0.3 0.2-0.6 <.001 0.3 0.1-0.5 <.001 
Maintenance∗  12 (14) 0.4 0.2-1.0 .04 0.4 0.1-1.0 .051 
TP53 mutation 13 (15) 2.4 1.3-4.6 .008 3.1 1.4-6.8 .005 
TP53 or 17p deletion 5 (6) 9.6 3.4-27.2 <.001 4.1 1.1-15.0 .03 
CDKN2A deletion 7 (8) 2.2 0.9-5.1 .07    
TET2 mutation 48 (55) 0.9 0.5-1.5 .69    
DNMT3A mutation 17 (20) 1.4 0.8-2.5 .27    
DNMT3A exon 23 mutation 5 (6) 1.4 0.6-3.6 .44    
RHOA mutation 26 (30) 0.8 0.4-1.3 .34    
FAT1 mutation 4 (5) 1.1 0.3-3.4 .92    
STAT3 mutation 4 (5) 1.0 0.3-3.3 .94    
SETD2 mutation 5 (6) 0.5 0.2-1.6 .24    
IDH2 mutation 7 (8) 0.6 0.2-1.7 .33    
PCLG1 mutation 7 (8) 1.2 0.5-2.9 .76    
Total number of aberrancies 87 (100) 1.0 1.0-1.1 .07    

Variable		n (%)Univariate analysisMultivariate analysis
HR95% CIPHR95% CIP
Age > 60 y 50 (57) 1.2 0.7-1.9 .56    
Stage III/IV 72 (83) 3.0 1.3-6.9 .01 5.1 1.1-22.5 .03 
Performance: ECOG PS ≥ 2 10 (11) 1.9 0.9-3.7 .08    
LDH elevated 53 (61) 1.1 0.7-1.9 .69    
BM involvement (by morphological assessment) 32 (37) 2.3 1.4-3.9 .002 3.0 1.1-8.4 .04 
Other extranodal sites of involvement 35 (40) 1.9 1.1-3.1 .01 1.5 0.7-3.3 .32 
IPI score        
0-1 17 (20) 1.0      
2 28 (32) 2.1 0.9-4.7 .08 1.0 0.2-4.3 .98 
3 30 (34) 2.9 1.3-6.5 .009 0.4 0.1-2.8 .35 
4-5 12 (14) 2.8 1.1-7.0 .03 0.1 0.01-2.0 .15 
PIT score        
0-1 44 (51) 1.0      
2 24 (28) 1.3 0.7-2.4 .37 1.3 0.4-3.8 .65 
3-4 19 (22) 2.2 1.2-4.1 .01 2.4 0.3-17.0 .41 
Histology        
PTCL-NOS 28 (32) 1.0      
PTCL-TFH 6 (7) 0.3 0.1-1.1 .08    
AITL 39 (45) 0.7 0.4-1.2 .14    
ALK+ ALCL 2 (2) 0.3 0.04-2.3 .24    
ALK− ALCL 8 (9) 0.4 0.1-1.2 .10    
MEITL 4 (5) 0.7 0.2-2.5 .61    
Use of etoposide-containing regimens 47 (54) 1.0 0.6-1.6 .91    
Use of BV-containing regimens 12 (14) 0.8 0.3-2.0 .65    
ASCT consolidation 37 (43) 0.3 0.2-0.6 <.001 0.3 0.1-0.5 <.001 
Maintenance∗  12 (14) 0.4 0.2-1.0 .04 0.4 0.1-1.0 .051 
TP53 mutation 13 (15) 2.4 1.3-4.6 .008 3.1 1.4-6.8 .005 
TP53 or 17p deletion 5 (6) 9.6 3.4-27.2 <.001 4.1 1.1-15.0 .03 
CDKN2A deletion 7 (8) 2.2 0.9-5.1 .07    
TET2 mutation 48 (55) 0.9 0.5-1.5 .69    
DNMT3A mutation 17 (20) 1.4 0.8-2.5 .27    
DNMT3A exon 23 mutation 5 (6) 1.4 0.6-3.6 .44    
RHOA mutation 26 (30) 0.8 0.4-1.3 .34    
FAT1 mutation 4 (5) 1.1 0.3-3.4 .92    
STAT3 mutation 4 (5) 1.0 0.3-3.3 .94    
SETD2 mutation 5 (6) 0.5 0.2-1.6 .24    
IDH2 mutation 7 (8) 0.6 0.2-1.7 .33    
PCLG1 mutation 7 (8) 1.2 0.5-2.9 .76    
Total number of aberrancies 87 (100) 1.0 1.0-1.1 .07    

ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase.

Bold indicates P < .05.

∗

Twelve patients received maintenance systemic therapy on a clinical trial either after chemotherapy or after ASCT.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal